You are here:  Home » Research Funding » Offices & Programs » Office of Translational Research » 

Skip secondary menu

Office of Translational Research



The mission of the NINDS Office of Translational Research (OTR) is to facilitate the preclinical discovery and development of new therapeutic interventions for neurological disorders.

Video: Dr. Rajesh Ranganathan Explains the NIH Blueprint Neurotherapeutics Network

Dr. Ranganathan’s presentation at the BIO Conference in May 2013: Office of Translational Research Introductory Presentation

The Office of Translational Research welcomes new Program Director, Dr. Hao Wang and Medical Officer Dr. Patricia Walicke.

The Small Business Program now has a twitter account: @NINDS_SmallBiz


Therapeutic Development Programs


View mode:

  • Target
    ID
  • Assay Development
  • Screen for
    Hit
  • Hit to
    Lead
  • Proof of Principle
  • Lead Optimization
  • Preclinical Safety/Tox
  • First in Human

  • Anticonvulsant Screening Program (ASP)

    • Provides services to characterize, optimize, and profile novel antiseizure/anticonvulsant agents by using a battery of disease-specific and mechanistic models of epilepsy (NINDS)

  • Exploratory/Developmental Projects in Translational Research

    • Provides funding (R21) for preclinical development tasks, including creation and validation of screening assays, development of animal models for therapy development, identification of candidate therapeutics, and development of preliminary animal efficacy data (NINDS)

  • Cooperative Program

    • Provides cooperative agreement funding (U01, U54, U24) for the preclinical development and testing of novel therapeutics and devices, in preparation for an IND/IDE (NINDS)

  • Small Business Program: SBIR & STTR

    • Provides funding (R41, R42, R43, R44, U44) to small businesses to engage in research and development with the potential for commercialization (NINDS)

  • Blueprint Neurotherapeutics Network

    • Provides cooperative agreement funding (U01) and free access to millions of dollars-worth of contracted drug development services and expertise to transform small molecule probe compounds into drug candidates for diseases and disorders of the nervous system (Trans-NIH)

  • Assay
    Development

    • Provides funding (R21) to develop and characterize assays that can be used to identify small molecule interactions via high-throughput screening of small molecular compound libraries and to chemically optimize active compounds as molecular probes (Trans-NIH)

  • Molecular
    Libraries

    • Provides funding (R03) and access to high-throughput screening services in the Molecular Libraries Probe Production Centers Network (Trans-NIH)

  • Lead Development

    • Supports investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes

  • BrIDGs

    • BrIDGs makes available certain critical resources needed for the development of new therapeutic agents. (Trans-NIH)

  • Countermeasures Against Chemical Threats (CounterACT)

    • Provides funding (U01, U54, R21, U44, contracts) and research services to develop products to prevent, diagnose, and treat the conditions caused by exposure to toxic chemicals (Trans-NIH)

Legend

  •  NINDS
  •  Trans-NIH


Download printer-friendly OTR Chart

Workshop Summary


Office of Translational Research Funding Initiatives


Office of Translational Research Program Staff


Scientific StaffResearch Area
Rajesh Ranganathan, Ph.D.
Associate Director

 
Rebecca Farkas, Ph.D.
Program Director

Blueprint Neurotherapeutics Network, Medicinal Chemistry, Roadmap Molecular Libraries
David Jett, Ph.D.
Program Director

Countermeasures (CounterACT) Programs, Neurotoxicology, Roadmap Molecular Libraries
Karrah Benson, B.S.
Program Coordinator

Anticonvulsant Screening Program (ASP)
Tracy Chen, Ph.D., D.A.B.T.
Scientific Research Specialist

Anticonvulsant Screening Program (ASP)
Charles Cywin, Ph.D.
Project Manager

Blueprint Neurotherapeutics Network
Stephanie Fertig, MBA
Research Project Manager

Small business (SBIR, STTR)
Karin French, M.S.
Program Analyst

Blueprint Neurotherapeutics Network
Adrienne Ivory, M.S.
Program Analyst

Blueprint Neurotherapeutics Network
John Kehne, Ph.D.
Program Director

Anticonvulsant Screening Program (ASP), Cooperative Agreement Program (CAP)
Linda McGavern, Ph.D.
Project Manager

NINDS Cooperative Program in Translational Research
Margaret Ochocinska, Ph.D.
Health Program Specialist

Anticonvulsant Screening Program (ASP), Countermeasures (CounterACT) Programs
Taek Oh
Information Technology Specialist

Anticonvulsant Screening Program (ASP)
Rebecca Roof, Ph.D.
Health Program Specialist

Small Business (SBIR, STTR)
Amir Tamiz, Ph.D.
Program Manager

Blueprint Neurotherapeutics Programs
Christina Vert, M.S.
Health Program Specialist

NINDS Cooperative Program in Translational Research
Patricia Walicke, MD, Ph.D.
Medical Officer

 
Hao Wang, Ph.D.
Program Director

Cooperative Agreement Program (CAP)
David Yeung, Ph.D.
Program Specialist/Project Manager

Countermeasures (CounterACT) Programs